ATPC Expands Global Market Footprint to Spearhead Medical Innovation with MoUs in Indonesia
ATPC has signed three Memorandums of Understanding (MOUs) with prominent Indonesian healthcare institutions to advance medical research and treatment strategies for respiratory diseases. The partnerships with Dr. Sardjito General Hospital, Dr. H. A. Rotinsulu Lung Hospital, and Dr. M. Goenawan Partowidigdo Respiratory Hospital focus on enhancing research capabilities, conducting clinical studies on ATPC's health products, and ensuring compliance with Indonesian health standards. The collaboration aims to address tuberculosis (TB) and chronic obstructive pulmonary disease (COPD), major health concerns in Indonesia, through advanced medical research, healthcare professional training, and innovative treatment approaches.
ATPC ha firmato tre Memorandum di Intesa (MoU) con importanti istituzioni sanitarie indonesiane per avanzare nella ricerca medica e nelle strategie di trattamento per le malattie respiratorie. Le collaborazioni con il Dr. Sardjito General Hospital, il Dr. H. A. Rotinsulu Lung Hospital e il Dr. M. Goenawan Partowidigdo Respiratory Hospital si concentrano sul potenziamento delle capacità di ricerca, sulla conduzione di studi clinici sui prodotti sanitari di ATPC, e sull'assicurare la conformità agli standard sanitari indonesiani. L'obiettivo della collaborazione è affrontare la tubercolosi (TB) e la broncopneumopatia cronica ostruttiva (BPCO), principali problematiche sanitarie in Indonesia, attraverso avanzate ricerche mediche, formazione di professionisti sanitari e approcci terapeutici innovativi.
ATPC ha firmado tres Memorandos de Entendimiento (MoUs) con destacadas instituciones de salud indonesias para avanzar en la investigación médica y las estrategias de tratamiento de enfermedades respiratorias. Las asociaciones con el Dr. Sardjito General Hospital, el Dr. H. A. Rotinsulu Lung Hospital y el Dr. M. Goenawan Partowidigdo Respiratory Hospital se centran en mejorar las capacidades de investigación, realizar estudios clínicos sobre los productos de salud de ATPC y garantizar el cumplimiento de los estándares de salud indonesios. La colaboración tiene como objetivo abordar la tuberculosis (TB) y la enfermedad pulmonar obstructiva crónica (EPOC), preocupaciones de salud importantes en Indonesia, a través de investigación médica avanzada, formación de profesionales de la salud y enfoques de tratamiento innovadores.
ATPC는 인도네시아의 주요 의료 기관들과 호흡기 질환에 대한 의학 연구 및 치료 전략을 발전시키기 위해 세 개의 양해각서를 체결했습니다. Dr. Sardjito General Hospital, Dr. H. A. Rotinsulu Lung Hospital, Dr. M. Goenawan Partowidigdo Respiratory Hospital와의 협력은 연구 능력 향상, ATPC 건강 제품에 대한 임상 연구 수행, 인도네시아 건강 기준 준수 보장을 중점적으로 다루고 있습니다. 이번 협력의 목표는 인도네시아에서 주요 건강 문제인 결핵(TB)과 만성폐쇄성폐질환(COPD)을 해결하기 위해 첨단 의학 연구, 의료 전문가 교육, 혁신적인 치료 접근 방식을 활용하는 것입니다.
ATPC a signé trois Mémorandums d'Entente (MoU) avec des institutions de santé indonésiennes de premier plan pour faire avancer la recherche médicale et les stratégies de traitement des maladies respiratoires. Les partenariats avec le Dr. Sardjito General Hospital, le Dr. H. A. Rotinsulu Lung Hospital et le Dr. M. Goenawan Partowidigdo Respiratory Hospital se concentrent sur l'amélioration des capacités de recherche, la réalisation d'études cliniques sur les produits de santé d'ATPC et l'assurance de la conformité aux normes de santé indonésiennes. La collaboration vise à traiter la tuberculose (TB) et la maladie pulmonaire obstructive chronique (BPCO), qui sont des préoccupations majeures de santé en Indonésie, par le biais de recherches médicales avancées, de la formation des professionnels de santé et d'approches de traitement innovantes.
ATPC hat drei Memoranden of Understanding (MoUs) mit prominenten indonesischen Gesundheitseinrichtungen unterzeichnet, um medizinische Forschung und Behandlungsstrategien für Atemwegserkrankungen voranzutreiben. Die Partnerschaften mit dem Dr. Sardjito General Hospital, dem Dr. H. A. Rotinsulu Lung Hospital und dem Dr. M. Goenawan Partowidigdo Respiratory Hospital konzentrieren sich auf die Verbesserung der Forschungskapazitäten, die Durchführung klinischer Studien zu ATPCs Gesundheitsprodukten und die Gewährleistung der Einhaltung indonesischer Gesundheitsstandards. Die Zusammenarbeit zielt darauf ab, Tuberkulose (TB) und chronisch obstruktive Lungenerkrankung (COPD), die erheblichen Gesundheitsprobleme in Indonesien sind, durch fortschrittliche medizinische Forschung, Schulung von Gesundheitsfachkräften und innovative Behandlungsansätze anzugehen.
- Strategic expansion into Indonesian healthcare market through partnerships with three major hospitals
- Clinical validation of existing products for Indonesian market compliance
- Access to large patient population for product development and testing
- Alignment with regulatory requirements for market distribution
- None.
Insights
The MOUs signed with three Indonesian healthcare institutions represent a strategic market expansion but lack immediate financial impact. While Indonesia's large population and high TB burden present significant market potential, these agreements are preliminary steps without concrete revenue commitments or defined monetary value. The focus on clinical studies and regulatory compliance suggests a long-term market entry strategy that may take 12-24 months to generate meaningful revenue.
The partnerships with government hospitals and presence of key regulatory officials (BPOM) indicate strong institutional backing, potentially expediting product approvals. However, success depends on clinical study outcomes and regulatory clearances. The target diseases (TB and COPD) represent substantial markets - Indonesia reports over 800,000 new TB cases annually, while COPD affects approximately 4.8% of the population.
Agreements to drive clinical research, enhance product safety, and combat respiratory diseases
KUALA LUMPUR, MALAYSIA / ACCESSWIRE / November 29, 2024 / NASDAQ-listed AGAPE ATP Corporation ("ATPC"), today announced the signing of three Memorandums of Understanding ("MOUs") with prominent healthcare institutions in Indonesia. This initiative aims to advance medical research, introduce innovative treatment strategies and strengthen training programs to address respiratory diseases such as tuberculosis (TB) and chronic obstructive pulmonary disease (COPD). The signing marks a key milestone in ATPC's strategic expansion plans in Indonesia and Southeast Asia.
 |  |  |
The MoUs were signed with Dr. Sardjito General Hospital in Yogyakarta, Dr. H. A. Rotinsulu Lung Hospital in Bandung, and Dr. M. Goenawan Partowidigdo Respiratory Hospital in Bogor. These partnerships focus on enhancing research capabilities, fostering medical innovations, and conducting clinical studies on ATPC's existing health products. These studies ensure the products comply with Indonesian health standards for safe consumption and use, meeting regulatory requirements prior to market distribution of ATPC's products.
Through these partnerships, ATPC reaffirms its commitment to maintaining the highest standards of safety and efficacy for its health products, further solidifying its position as a trusted innovator in the healthcare industry.
The collaborations are built on a shared vision to address critical global health challenges. Together, the parties aim to foster interdisciplinary collaboration, knowledge exchange, and sustainable health practices. Key initiatives include advanced medical research, healthcare professional training, and the introduction of innovative approaches to combat respiratory diseases. The partnerships also aim to connect with international universities and specialist hospitals to further elevate healthcare standards.
Prof Dato' Sri Dr How Kok Choong, the Founder and Global Group CEO of ATPC said, "TB and COPD remain major public health concerns in both Indonesia and Malaysia. Indonesia ranks among the countries with the highest TB burden globally, with hundreds of thousands of new cases reported annually. Meanwhile, COPD, often linked to high rates of smoking and air pollution, significantly contributes to illness and mortality in both nations. These diseases place immense strain on healthcare systems, highlighting the urgent need for collaborative efforts to improve prevention, diagnosis, and treatment strategies."
"Our partnerships reflect ATPC's unwavering commitment to leveraging global expertise and advancing healthcare innovation. By conducting rigorous clinical studies and aligning with Indonesia's Ministry of Health standards, we aim to ensure that products and services like DSY Wellness, ATP2 and LEGA effectively meet the needs of patients battling respiratory diseases. This marks a pivotal step toward creating a healthier, more sustainable future. We look forward to exploring new collaborations that will further enhance our contributions to Southeast Asia's healthcare ecosystem."
These partnerships also emphasize the integration of sustainable medical innovations, aiming to enhance long-term well-being and align with the United Nations Sustainable Development Goals ("UNSDG"). Through these collaborations, ATPC reinforces its role as a global leader in wellness and healthcare, advancing scientific research and sustainable health outcomes.
The MoU signing ceremony was graced by distinguished guests from the Indonesian Ministry of Health, including Dr. Suranto M.Kes, Director of Health Service Governance, and Prof. Dr. Taruna Ikrar, Head of the Food and Drug Supervisory Authority (BPOM), an agency under the Ministry of Health. Also present were representatives from ATPC, including Prof. Dato' Sri Dr. How Kok Choong, Founder and Group CEO; Dr. John Vong, Deputy Chairman; and Dr. Fernando Cortizo, Executive Director.
About AGAPE ATP Corporation
Agape ATP Corporation (ATPC) is dedicated to enhancing the quality of life and promoting sustainable development. With a strong foundation built on two core business pillars, ATPC specialises in the provision of health and wellness products that caters to the diverse needs of its customers, ensuring their well-being and vitality. Additionally, APTC delivers comprehensive energy-saving solutions that empower companies to drive sustainability initiatives, reduce energy consumption, and achieve their sustainability goals.
For more information, visit www.agapeatpgroup.com.
Issued By: Koa International Sdn. Bhd. on behalf of Agape ATP Corporation
For more information, please contact:
Jazzmin Wan
Tel: +60 17-289 4110
Email:j.wan@swanconsultancy.biz
Mandy Tan
Tel: +60 16-477 2257
Email:m.tan@swanconsultancy.biz
FORWARD-LOOKING STATEMENT
Certain statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected benefits and outcomes of the partnerships announced by AGAPE ATP Corporation ("ATPC") and the potential for medical innovations and healthcare advancements through these collaborations. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the Company's ability to execute its strategies, manage growth, and maintain its corporate culture; the Company's future business development, financial conditions, and results of operations; expectations regarding demand for and market acceptance of our products and services; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in Malaysia and the international markets the Company plans to serve, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and AGAPE ATP Corporation specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.
SOURCE: Agape ATP Corporation
View the original press release on accesswire.com
FAQ
What partnerships did ATPC announce in Indonesia on November 29, 2024?
What is the main purpose of ATPC's MOUs with Indonesian hospitals?
Which ATPC products will be studied in Indonesian clinical trials?
Who were the key officials present at ATPC's MOU signing in Indonesia?
